Microdosing tirzepatide runs a five-step ladder: 0.5 → 1 → 1.5 → 2 → 2.5 mg weekly. Each step has a distinct effect profile. At 1 mg, expect about 4 lb off by 3 months, 9 lb by 6 months for a 220 lb baseline. At 2 mg, 7 lb and 15 lb. At 0.5 mg, subtle body-composition drift over years with meaningful insulin-sensitivity improvement and no meaningful GI burden. Most weight loss at any microdose step lands by month 6; month 12 is the plateau. The nausea and appetite effects that force many users off the 5–15 mg therapeutic doses stay at placebo levels through the entire microdose band — the mechanism is specifically different at low dose.
Users pick a step and sit, or titrate up until the response lands. The full label ladder (2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg) is one path; staying at 2.5 mg chronically is another; the 1–2 mg microdose band is a third. Microdose is the wrong tool for rapid weight loss — for that, 5–10 mg is what the SURMOUNT-1 trial characterized, with 15–21% weight loss at 72 weeks.³
| At a Glance | |
|---|---|
| Dosage | 0.5–2.5 mg subcutaneous weekly, typically split into two injections every 3.5 days. |
| Protocol | Pick a step and sit, or titrate up from 1 mg until response lands. Chronic 2.5 mg is a standalone destination, not just a titration starter. |
| Expected results, 220 lb baseline | 0.5 mg: ~3 lb by 3 mo, ~7 lb by 18 mo. 1 mg: ~4 lb / ~9 lb. 2 mg: ~7 lb / ~15 lb. 2.5 mg: ~7 lb / ~20 lb. Plateau by month 12 at every step. |
| Side effects | 0.5–1 mg: tracks placebo in trials. 1.5–2 mg: mild and occasional. 2.5 mg: brief GI sensation early, fades by week 6. 5 mg and above: nausea and GI effects scale sharply with dose. |
| Regulatory status | Tirzepatide is FDA-approved for T2D (Mounjaro) and chronic weight management (Zepbound). Doses below 2.5 mg are off-label. |
| Best stacked with | NAD+, Tesamorelin — see Dual-Axis Protocol. |
The Dose Band
The microdose ladder runs 0.5 → 1 → 1.5 → 2 → 2.5 mg weekly. Each step has its own signature.
0.5 mg weekly sits below endogenous meal-stimulated receptor engagement on both axes, but the drug engagement is sustained 24/7 versus the 30–60 minute transient spikes meals produce. Integrated across a week, 0.5 mg delivers more total receptor-hours than meals alone. The body-composition effect is subtle — roughly 2 lb drug-attributable over 18 months for a 220 lb baseline — but the insulin-sensitivity marker (fasting insulin ~7% reduction) is real. This is the step for someone metabolically healthy, optimizing for long-horizon body-comp drift, not the scale.
1 mg weekly is the lowest dose with published human trial data — the Phase 2 T2D arm (NCT03131687).¹ Fasting insulin drops ~14%. Weight comes off at ~4 lb by 3 months, ~9 lb by 18 months. GI effects track placebo.
1.5 mg weekly is the step-up point. Weight effect moves to ~5 lb by 3 months, ~11 lb by 18 months. Fasting insulin ~19%. Still below the nausea threshold.
2 mg weekly is where the curve starts producing real numbers — ~7 lb by 3 months, ~15 lb by 18 months. Fasting insulin ~22%. Appetite effects become mildly noticeable, occasionally.
2.5 mg weekly is the label's titration starter, but chronic 2.5 mg is its own protocol. Trial protocols escalate through it for four weeks before moving to 5 mg. Users who stay at 2.5 mg indefinitely land around ~20 lb over 18 months with mild GI effects that typically fade by week 6. The dose has not been trialed as a chronic destination — it's been used as a step — so the long-tail effect profile is extrapolated, not measured.
Above 5 mg, you enter the characterized therapeutic band, where SURMOUNT-1 directly measured the full dose-response at 72 weeks.³
Weekly Trajectory — 220 lb baseline
| Dose | 3 mo (12 wk) | 6 mo (24 wk) | 1 yr (48 wk) | 1.5 yr (72 wk) |
|---|---|---|---|---|
| 0.5 mg/wk | ~3 lb | ~6 lb | ~7 lb | ~7 lb |
| 1 mg/wk (split) | ~4 lb | ~7 lb | ~9 lb | ~9 lb |
| 1.5 mg/wk (split) | ~6 lb | ~9 lb | ~11 lb | ~11 lb |
| 2 mg/wk (split) | ~7 lb | ~11 lb | ~15 lb | ~15 lb |
| 2.5 mg/wk | ~7 lb | ~13 lb | ~18 lb | ~20 lb |
| 5 mg/wk | ~11 lb | ~24 lb | ~31 lb | ~35 lb |
| 7.5 mg/wk | ~13 lb | ~29 lb | ~37 lb | ~42 lb |
| 10 mg/wk | ~15 lb | ~33 lb | ~44 lb | ~49 lb |
| 12.5 mg/wk | ~18 lb | ~35 lb | ~46 lb | ~51 lb |
| 15 mg/wk | ~18 lb | ~35 lb | ~49 lb | ~53 lb |
5/10/15 mg are SURMOUNT-1 Figure S5 observed. 7.5 and 12.5 mg are linear interpolations between observed label-ladder steps. 0.5–2.5 mg extrapolated from the Phase 2 anchor using linear pharmacokinetics and matched-timepoint population multipliers — derivation in appendix.
Across every dose in SURMOUNT-1, roughly 70% of the full 72-week weight loss is already on the scoreboard by week 24. Most of the journey happens in the first six months; the next year is plateau. A microdose user who hasn't seen the expected 3- and 6-month numbers should not expect a late acceleration.
The Receptor Math
Tirzepatide is often described as a stronger GLP-1 drug. That framing gets the mechanism wrong. Tirzepatide binds the GIP receptor with affinity equal to the body's native GIP hormone, and binds the GLP-1 receptor with roughly 5× weaker affinity than native GLP-1.² The molecule was engineered this way deliberately. GLP-1 receptor activation drives nausea, gastric slowing, and the appetite suppression that forces many users off the drug. GIP receptor activation drives insulin efficiency and fat-cell thermogenesis without those side effects.
The imbalance is not just preserved at low dose — it is amplified. At therapeutic doses, GIP receptors approach saturation while GLP-1 receptors are still climbing, compressing the advantage. At microdose, both sit on the steep part of their curves, and the GIP-to-GLP-1 engagement ratio widens.
Lilly's pharmacology team published receptor occupancy at clinical doses.² Extending the same formula across the microdose band with tirzepatide's linear pharmacokinetics gives occupancy at every step.
Predicted receptor occupancy at each weekly dose
| Dose | GIP receptor | GLP-1 receptor | GIP:GLP-1 ratio |
|---|---|---|---|
| 0.5 mg | 2.2% | 0.35% | 6.3× |
| 1 mg | 4.4% | 0.70% | 6.3× |
| 1.5 mg | 6.4% | 1.1% | 5.9× |
| 2 mg | 8.4% | 1.4% | 6.0× |
| 2.5 mg | 10.3% | 1.7% | 5.9× |
| 5 mg | 19% | 3% | 6.3× |
| 10 mg | 32% | 7% | 4.6× |
| 15 mg | 41% | 10% | 4.1× |
After a meal, the body itself produces enough GLP-1 to engage 1–4% of GLP-1 receptors and enough GIP to engage 4–20% of GIP receptors.² These are the biological baselines your physiology runs every time you eat. Both are transient — 30–60 minutes postprandial, then back to near-zero between meals.
Tirzepatide delivers its occupancy sustained, 24/7. That distinction is the interpretive key. At 0.5 mg weekly, the instantaneous occupancy (0.35% GLP-1R, 2.2% GIPR) sits below the peak of a meal-stimulated response, but the integrated receptor-hours per week exceed what three meals produce. The drug isn't competing with a meal at any given moment; it's running underneath the baseline all the time.
At 1 mg weekly, GLP-1 receptor occupancy is below what the body produces after a meal. The Phase 2 trial measured nausea at 3.8% — below the 5.9% placebo rate.¹ At 2 mg, GLP-1 occupancy reaches 1.4%, inside the lower end of the endogenous meal range. The jump to 5 mg brings occupancy to 3% (inside normal postprandial range, but sustained), and 5 mg is where appreciable nausea starts appearing in trials. At 10 mg and above, GLP-1 occupancy exceeds 2× the endogenous baseline, and nausea rates reach 30–40% at 15 mg.¹
GIP receptor occupancy at 0.5–2.5 mg sits at 2–10% — inside the endogenous meal-stimulated range, sustained through the week. This is the load-bearing mechanism of the microdose.
GIP at the Fat Cell
Yu et al. (2025) generated mice with GIP receptor overexpression restricted to adipocytes and characterized what GIP receptor activation in fat cells does: the cell uses ATP to pump calcium into the endoplasmic reticulum while calcium simultaneously leaks back out, producing heat without productive work (SERCA-mediated futile calcium cycling⁴). Adipocyte-specific GIP receptor induction alone produced 35% weight loss in obese mice. The mechanism was confirmed by knocking out the SERCA calcium pump, which abolished the effect. Weight loss persisted after the receptor was switched off — a "metabolic memory" phenomenon that distinguishes GIP-driven weight loss from GLP-1-driven weight loss.
The effect decomposes into two phases. During days 2–7, there's a transient drop in food intake driven by signaling from adipose tissue back to the hypothalamus. After roughly one week, food intake normalizes, and sustained weight loss is carried by increased energy expenditure — local heat production, lipid oxidation, reduced systemic triglycerides. The first week feels different (mild appetite shift), but the persistent effect after is metabolic, not anorectic.
Metabolic markers across the band
SURMOUNT-1 reported non-diabetic metabolic changes at therapeutic doses. Extending the same dose-response ratios from Phase 2 T2D HbA1c data to the microdose band produces projected metabolic effects at each step (placebo-adjusted, 72 weeks):
| Dose | HbA1c Δ | Fasting insulin Δ | Fasting glucose Δ |
|---|---|---|---|
| 0.5 mg | ~−0.08% | ~−7% | ~−2 mg/dL |
| 1 mg | ~−0.15% | ~−14% | ~−3 mg/dL |
| 1.5 mg | ~−0.20% | ~−19% | ~−4 mg/dL |
| 2 mg | ~−0.23% | ~−22% | ~−6 mg/dL |
| 2.5 mg | ~−0.25% | ~−25% | ~−7 mg/dL |
| 5 mg | −0.33% | −32% | −8.6 mg/dL |
| 10 mg | −0.42% | −39% | −10.6 mg/dL |
| 15 mg | −0.44% | −39% | −11.5 mg/dL |
The fasting insulin column is the load-bearing number for non-diabetic users. Even 0.5 mg produces a measurable improvement in insulin sensitivity. HbA1c effects are small in absolute terms because non-diabetic baseline HbA1c is already near the floor; fasting insulin is the better marker for metabolic improvement in this population.
Split-Dosing
Tirzepatide has a half-life of 5.4 days (Schneck 2024 population PK model⁵), reaches steady state after four weekly doses, and has an accumulation ratio of 1.58. Weekly dosing already produces a relatively stable plasma curve — not the dramatic peak-to-trough swings that characterize shorter-acting peptides. The "splitting smooths the rollercoaster" framing that appears in a lot of microdose content overstates how jagged the baseline actually is.
Splitting a 1 mg weekly dose into two 0.5 mg injections every 3.5 days matters for a subtler reason. At microdose, GIP receptors sit at 2–10% occupancy — on the steep part of the dose-response curve. Keeping plasma exposure more stable preserves trough concentrations above the threshold where signaling turns on. At therapeutic doses, you are already past saturation for most of the week regardless of splitting, so the PK flattening adds less value. At microdose, preserving the low end of the curve is where effect actually lives.
A practical split: Monday morning and Thursday evening, with injection-site rotation between visits. The total weekly dose is identical; the plasma curve is modestly flatter.
Body Composition
In the SURMOUNT-1 DXA substudy (160 participants, 72 weeks, therapeutic doses), weight loss was split 75:25 fat-to-lean.⁶ Semaglutide users in the STEP-1 substudy landed closer to 60:40 — roughly 40% of weight loss from lean mass.⁷ On the relative axis, tirzepatide is more favorable.
The absolute axis is more nuanced. Sattar et al. (2025) analyzed MRI muscle composition in SURPASS-3 and found tirzepatide users lost muscle volume proportional to their weight loss — in line with UK Biobank predictions for anyone losing that much weight.⁸ The muscle that stayed was of higher quality (significantly less fat infiltration than predicted). Muscle quality improved; volume did not get spared against the scale.
For a microdose user: 9 lb at 1 mg or 15 lb at 2 mg includes roughly 2–4 lb of lean mass. The muscle that remains is metabolically healthier. Resistance training and adequate protein during weight loss remain necessary — the drug does not replace them.
Who This Isn't For
- Personal or family history of medullary thyroid carcinoma, or MEN2 syndrome — contraindicated
- Prior pancreatitis — contraindicated
- Current insulin users — requires physician management of hypoglycemia risk
- Pregnancy or breastfeeding — contraindicated
Protocol
Tirzepatide pens (Zepbound, Mounjaro) do not dose below 2.5 mg. Microdosing is only accessible through compounded vials — lyophilized tirzepatide reconstituted with bacteriostatic water. The volume drawn depends on how much BAC water was added.
Reconstitution chart (U-100 insulin syringe, 1 mL = 100 units)
| Vial Size | BAC Water | Concentration | 0.5 mg draw | 1.0 mg draw | 2.0 mg draw |
|---|---|---|---|---|---|
| 5 mg | 1 mL | 5 mg/mL | 10 units | 20 units | 40 units |
| 10 mg | 2 mL | 5 mg/mL | 10 units | 20 units | 40 units |
| 15 mg | 3 mL | 5 mg/mL | 10 units | 20 units | 40 units |
| 30 mg | 6 mL | 5 mg/mL | 10 units | 20 units | 40 units |
For custom dose calculation: Units = (Dose mg ÷ Concentration mg/mL) × 100
For automated math and split-dose scheduling, use the Tirzepatide Dosage Calculator.
Week-by-week expectation at 1–2 mg weekly
- Weeks 1–2: Subtle food-noise reduction. Mild GI sensation possible the day after injection. Scale weight may drop 1–2 lb, much of it water.
- Weeks 3–8: Appetite suppression normalizes as the transient central effect fades.⁴ Sustained energy expenditure takes over. Weight loss pace is steady — roughly 0.5–1 lb per week at 2 mg, half that at 1 mg.
- Months 3–6: Most of the total weight loss occurs in this window. The trajectory bends toward plateau around month 5–6.
- Months 7–18: Plateau. Small additional loss continues through month 12, then maintenance.
Maintenance and Step-Down
For someone on a therapeutic dose wanting to step down after reaching goal weight, the dose-response curve argues for stop-short rather than maintenance at 15 mg. Stopping at 5 mg preserves roughly 70% of the full 15 mg weight-loss effect; stopping at 10 mg preserves 93%.³ The incremental gain from 10 to 15 mg is 1.4 percentage points of additional weight loss over 72 weeks.
Stepping down to the microdose band (1–2.5 mg) is a further move. GLP-1 receptor engagement drops below the endogenous meal-stimulated range, eliminating most of the GI side-effect burden, while GIP receptor engagement stays within the range that drives adipose thermogenesis. A common step-down sequence: 15 → 10 → 7.5 → 5 → 2.5 → 2 → 1.5 → 1 mg in 8–12 week increments.
SURMOUNT-4 established that full discontinuation causes substantial weight regain — 14% within a year for those switched to placebo.¹⁰ Step-down to microdose is not the same as stopping; the mechanism is still engaged, just calibrated for maintenance rather than active weight loss.
FAQ
What is considered a microdose of tirzepatide?
A microdose is any weekly dose below 2.5 mg — the label's titration-starter floor. The practical microdose ladder is 0.5 → 1 → 1.5 → 2 → 2.5 mg weekly, typically split into two injections every 3.5 days. 1 mg is the lowest dose with published Phase 2 trial data.¹
Does microdosing tirzepatide work for weight loss?
At 1 mg weekly, expect about 4 lb by 3 months and 9 lb by 18 months for a 220 lb baseline. At 2 mg, 7 lb and 15 lb. At 0.5 mg, body-composition change is subtle — 2–3 lb drug-attributable over 18 months — but fasting insulin drops ~7%, meaningful for insulin-sensitivity maintenance. The mechanism is GIP-driven adipose thermogenesis rather than the full GLP-1 appetite suppression seen at 5–15 mg.⁴
How do you microdose tirzepatide for maintenance?
After reaching goal weight on a therapeutic dose, step down gradually — typically 15 → 10 → 7.5 → 5 → 2.5 → 2 → 1 mg in 8–12 week increments. At the microdose band, split the weekly dose into two injections 3.5 days apart to keep plasma exposure stable. The goal is preserving GIP receptor engagement (which drives fat-cell thermogenesis) without maintaining high GLP-1 receptor engagement (which drives the GI side-effect burden).
How much volume do I draw for a tirzepatide microdose?
Compounded tirzepatide volumes depend on how much BAC water was added during reconstitution. A 10 mg vial reconstituted with 2 mL of BAC water produces a 5 mg/mL concentration: a 1 mg dose requires 0.2 mL (20 units on a standard U-100 insulin syringe), and a 0.5 mg split-dose requires 0.1 mL (10 units). See the reconstitution chart above, or use the Tirzepatide Dosage Calculator.
Can I keep my tirzepatide dose at 2.5 mg instead of titrating up?
Yes. Chronic 2.5 mg produces ~20 lb weight loss at 72 weeks for a 220 lb baseline, with fasting insulin ~−25% and mild GI effects that fade by week 6. The label positions 2.5 mg as a titration starter, not a destination — it has not been trialed as chronic therapy — but the receptor occupancy and PK data don't prohibit it.
Appendix
The microdose projection extends from one directly measured human anchor: the 1 mg arm of NCT03131687 Phase 2 in T2D patients, 26 weeks, 318 participants.¹ That arm produced −0.9 kg body weight change on a baseline around 92 kg (−1.0%). Two adjustments extend this to a non-diabetic user over 72 weeks.
Population multiplier — T2D → non-diabetic, matched 24-wk timepoint
| Dose | T2D 26 wk (Phase 2) | Non-diabetic 24 wk (SURMOUNT-1) | Ratio |
|---|---|---|---|
| 5 mg | −5.2% | −10.8% | 2.08× |
| 10 mg | −9.5% | −14.6% | 1.54× |
| 15 mg | −12.3% | −15.3% | 1.24× |
The multiplier is larger at lower doses — GIP receptors are less saturated and the responsive-pathway advantage of a non-diabetic population is amplified. Extrapolating the trend, 1 mg sits at approximately 2.2×; 0.5 mg at ~2.3×.
Time multiplier — 24 wk → 72 wk within SURMOUNT-1
| Dose | 24 wk placebo-adj | 72 wk placebo-adj | Ratio |
|---|---|---|---|
| 5 mg | −8.9% | −13.2% | 1.48× |
| 10 mg | −12.7% | −18.9% | 1.49× |
| 15 mg | −13.3% | −20.2% | 1.52× |
The ratio is stable at 1.48–1.52× across doses. About 70% of the full 72-week weight loss arrives by week 24 regardless of dose.
Applied to the microdose band
Phase 2 1 mg arm produced −0.55% weight change relative to placebo at 26 weeks. Applying the population multiplier (2.2×) gives −1.2% at 24 weeks non-diabetic. Applying the time multiplier (1.48×) gives −1.8% at 72 weeks. Adding the placebo trajectory from SURMOUNT-1 (−2.4%) gives −4.2% total weight change at 72 weeks — about 9 lb for a 220 lb baseline. Every other microdose step follows the same chain, interpolated between 1 mg and 5 mg at the Phase 2 anchor.
Receptor occupancy formula
Willard 2020 (Table 1) publishes predicted receptor occupancy for 5/10/15 mg tirzepatide using:
pRO = [free drug] / ([free drug] + EC50)
With:
- GIPR cAMP EC50: 1.01 nM (albumin-free assay)
- GLP-1R cAMP EC50: 6.54 nM
- Free plasma fraction: ~0.29% of total Cav,ss (tight albumin binding)
- Plasma Cav,ss scales linearly across 0.25–15 mg (Schneck 2024 population PK)
Extending the same formula to 0.5–2.5 mg using linear PK produces the occupancy values in the main table. Reproducing the published 5/10/15 mg values (19% / 32% / 41% GIPR; 3% / 7% / 10% GLP-1R) served as verification before extrapolation.
Metabolic marker extrapolation
HbA1c and fasting insulin projections at the microdose band use the glycemic dose-response ratios from Phase 2 T2D (1 mg produced 40–55% of 15 mg's HbA1c effect) applied to SURMOUNT-1 non-diabetic baseline metabolic changes at 5/10/15 mg. Glycemic endpoints saturate earlier than weight endpoints, which is why 1 mg gets ~15% of 5 mg's weight effect but ~45% of its HbA1c effect.
Trial data sources
- NCT03131687 Phase 2 T2D, 26 weeks — 1 mg arm anchor
- NCT04184622 SURMOUNT-1, non-diabetic, 72 weeks — dose-response and weekly trajectory (Figure S5)
- NCT04657003 SURMOUNT-2, T2D + obesity, 72 weeks — T2D comparator at 72 weeks
- NCT03987919 SURPASS-2, T2D on metformin, 40 weeks — intermediate T2D timepoint
Weight-loss percentages are treatment-regimen (intent-to-treat) estimand throughout.
References
¹ Phase 2 dose-range T2D trial — NCT03131687, tirzepatide 1/5/10/15 mg vs placebo and dulaglutide, 318 participants, 26 weeks; 1 mg arm produced HbA1c −0.7% (observed) / −1.06% (Bayesian dose-response) and body weight −0.9 kg with nausea 3.8%: ClinicalTrials.gov · Frias Lancet 2018
² Tirzepatide imbalanced and biased dual agonism — GIPR binding affinity equal to native GIP, GLP-1R 5× weaker than native GLP-1; cAMP EC50 of 1.01 nM (GIPR) and 6.54 nM (GLP-1R); predicted receptor occupancy at clinical doses published in Table 1, with endogenous meal-stimulated baselines GLP-1R 1–4% and GIPR 4–20%: Willard JCI Insight 2020
³ SURMOUNT-1 72-week dose response — NCT04184622, 2,539 non-diabetic adults with obesity, 5/10/15 mg weekly vs placebo; treatment-regimen weight loss −15.0% / −19.5% / −20.9%; Figure S5 in supplementary appendix provides full weekly trajectory: Jastreboff NEJM 2022 · ClinicalTrials.gov
⁴ Adipocyte GIPR drives SERCA-mediated futile calcium cycling — Yu et al. 2025; adiponectin-promoter-driven GIPR induction in mouse adipocytes produced 35% weight loss at 2 weeks post-induction; SERCA2 CRISPR knockout abolished the thermogenic effect; adipose-to-brain signaling drives transient appetite suppression (days 2–7) followed by sustained energy expenditure: Cell Metab 2025
⁵ Tirzepatide population pharmacokinetics — Schneck 2024, pooled analysis of 5,802 participants across 19 studies; half-life 5.4 days, CL/F 0.0329 L/h per 70 kg, linear dose-proportionality 0.25–15 mg, steady state by week 4, accumulation ratio 1.58: CPT:PSP 2024
⁶ SURMOUNT-1 body composition DXA substudy — 160 participants, pooled 5/10/15 mg vs placebo at 72 weeks; total fat mass change −33.9% vs −8.2% placebo; total lean mass change −10.9% vs −2.6% placebo; 75:25 fat-to-lean loss ratio consistent across tirzepatide doses: Look et al. DOM 2025
⁷ STEP-1 body composition substudy — Wilding et al., exploratory DXA analysis of the STEP 1 trial; semaglutide 2.4 mg at 68 weeks; fat mass change −19.3% (8.36 kg), lean mass change −9.7% (5.26 kg); ~40% of total weight loss attributable to lean mass: Diabetes Obes Metab 2021 · STEP 1 main trial: Wilding NEJM 2021
⁸ SURPASS-3 MRI muscle composition substudy — Sattar et al. 2025, 246 T2D participants at 52 weeks, pooled tirzepatide 5/10/15 mg vs insulin degludec; muscle volume loss in line with UK Biobank weight-loss-predicted changes (mean difference −0.04 L, p=0.22); muscle fat infiltration improved significantly more than predicted (−0.42 percentage points, p<0.0001): Lancet Diabetes Endocrinol 2025
⁹ SURMOUNT-MAINTAIN — NCT06047548, tirzepatide maintenance dosing after weight-loss phase; primary endpoint: percent maintenance of body weight reduction at Week 112; ongoing: ClinicalTrials.gov
¹⁰ SURMOUNT-4 withdrawal vs continuation — NCT04660643, 36-week open-label lead-in followed by randomized continuation vs placebo for 52 weeks; continuators maintained 89.5% of initial weight loss, placebo-switchers regained 14% of body weight: Aronne JAMA 2024
Medical Disclaimer
The content in this protocol guide is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.